Zhejiang Starry Pharmaceutical (603520.SH) disclosed the third quarter report for 2024, achieving revenue of 18....
Zhongtong Finance APP news, Zhejiang Starry Pharmaceutical (603520.SH) disclosed the third quarter report for 2024, achieving revenue of 1.805 billion yuan, a year-on-year growth of 10.65%; net income attributable to the mother 8.98 million yuan, a year-on-year decrease of 77.17%; non-net profit 4.34 million yuan, a year-on-year decrease of 84.06%; basic earnings per share 0.02 yuan.